Biden-Harris: Price Cuts on 10 Drugs to Save Medicare Beneficiaries $1.5 Billion
Historic Medicare drug price negotiations to lower costs on 10 best-selling drugs, saving beneficiaries $1.5 billion in out-of-pocket costs in the program's first year.
The Biden-Harris administration announced Thursday that for the first time in history, Medicare can now negotiate drug prices, thanks to the Inflation Reduction Act, which was signed into law in 2022 by President Biden with Vice President Harris casting the tie-breaking vote.
The negotiation program could lead to an estimated $6 billion in savings on prescription drug costs for American taxpayers. People enrolled in Medicare with Medicare Part D prescription drug coverage are expected to save $1.5 billion in out-of-pocket costs beginning in 2026. The Congressional Budget Office estimated that the program will save Medicare $100 billion over the next ten years.
“It’s a relief for the millions of seniors that take these drugs to treat everything from heart failure, blood clots, diabetes, arthritis, Crohn’s disease, and more – and it’s a relief for American taxpayers,” Biden said at Biden’s and Harris’ first joint appearance since Biden announced he would not run for reelection.
Sign up for Kiplinger’s Free E-Newsletters
Profit and prosper with the best of expert advice on investing, taxes, retirement, personal finance and more - straight to your e-mail.
Profit and prosper with the best of expert advice - straight to your e-mail.
10 drugs to see price cuts of up to 79% off the 2023 list price
Since being first introduced to the market, manufacturers have steadily increased the list prices on the first 10 drugs selected for the Medicare drug price negotiation program. These drugs are among the highest total spending in Medicare Part D.
The new Medicare negotiated drug prices will cut the list prices on these drugs by between 38% and 79%, according to the Department of Health and Human Services (HHS). However, these figures don’t consider or account for the rebates and discounts that drugmakers already provide to Part D plans, information that has not been released publicly.
“I’ve been waiting for this moment for a long long time,” President Joe Biden said Thursday, during his first policy-oriented appearance with Vice President Kamala Harris since leaving the presidential race. “We pay more for prescription drugs, it’s not hyperbole, than any advanced nation in the world.”
Despite pharmaceutical companies' attempts to quash the program in federal court, the price cuts have been approved.
The 10 medications and the discounts off the 2023 list prices are as follows:
- Imbruvica: 38%
- Entresto: 53%
- Eliquis: 56%
- Xarelto: 62%
- Stelara: 66%
- Jardiance: 66%
- Enbrel: 67%
- Farxiga: 68%
- Fiasp/NovoLog: 76%
- Januvia: 79%
Seniors and people with disabilities who are on Medicare and take these drugs will also benefit from the Inflation Reduction Act’s $2,000 cap on out-of-pocket spending, which goes into effect in 2025. The cap will save 19 million beneficiaries an average of $400 per year. That's in addition to the savings from the new negotiated drug prices.
“Two years ago, as vice president, I was proud to cast the tie-breaking vote that gave Medicare the power to negotiate,” Vice President Harris said to cheering crowds. “In the two years since, we’ve been using this new power to lower the price of life-saving medication.” To illustrate, if a Medicare enrollee takes Stelara for arthritis and pays $3,459 for a 30-day supply today, they would pay only $1,174 in 2026.
And this is just the beginning. As part of Medicare’s drug price negotiation program, more drugs will be selected each year. Up to 15 additional prescription medications covered under Part D will be selected for negotiation in 2025, up to an additional 15 Part B and D drugs in 2026, and up to 20 drugs every year after that.
Among the fanfare, Steve Ubl, the president of the lobbying group Pharmaceutical Research and Manufacturers of America (PhRMA) noted, “The administration is using the IRA’s price-setting scheme to drive political headlines, but patients will be disappointed when they find out what it means for them.”
Related Content
Get Kiplinger Today newsletter — free
Profit and prosper with the best of Kiplinger's advice on investing, taxes, retirement, personal finance and much more. Delivered daily. Enter your email in the box and click Sign Me Up.
For the past 18+ years, Kathryn has highlighted the humanity in personal finance by shaping stories that identify the opportunities and obstacles in managing a person's finances. All the same, she’ll jump on other equally important topics if needed. Kathryn graduated with a degree in Journalism and lives in Duluth, Minnesota. She joined Kiplinger in 2023 as a contributor.
-
Affordability Crisis: Floridians Vote to Increase Property Tax Break
State Tax Property taxes have skyrocketed nearly 60% within the last five years in Florida, and its constituents are finally doing something about it.
By Gabriella Cruz-Martínez Published
-
Average Net Worth by Age: How Do You Measure Up?
Financial advisors discuss the secrets to growing your net worth over time.
By Adam Shell Published
-
Average Net Worth by Age: How Do You Measure Up?
Financial advisors discuss the secrets to growing your net worth over time.
By Adam Shell Published
-
Three Charitable Giving Strategies for High-Net-Worth Individuals
If you have $1 million or more saved for retirement, these charitable giving strategies can help you give efficiently and save on taxes.
By Joe F. Schmitz Jr., CFP®, ChFC® Published
-
The Wealth-Building Powers of Health Savings Accounts (HSAs)
Health savings accounts could be the most underutilized wealth-building tool out there. Here’s who should use them and how to maximize their benefits.
By Eric Roberge, Certified Financial Planner (CFP) and Investment Adviser Published
-
One Good Way to Withdraw Retirement Assets (and a Bad One)
Don't withdraw retirement assets haphazardly. Managing distributions intentionally can lower your taxes, conserve your wealth and reduce Medicare premiums.
By Justin Haywood, CFP® Published
-
What Is Capital Gains Tax Deferral?
Spoiler alert: It's the secret weapon of savvy real estate investors. Here's how it works and details about the tools you need to do it.
By Daniel Goodwin Published
-
Don't Leave Your Heirs an IRA Tax Bomb
Your traditional IRA has served you well, but when your heirs inherit it, watch out. Consider some of these strategies to minimize their tax burdens.
By Kelsey M. Simasko, Esq. Published
-
Become a Digital Nomad: An Early Retirement Lifestyle
Embrace a digital nomad lifestyle to satisfy your wanderlust. Here are tips from an ultramarathon runner, a professional blogger and a financial planner.
By Jacob Schroeder Published
-
What Social Security Beneficiaries Should Know About 2025 Numbers
Declining inflation led to the lowest cost-of-living adjustment since 2020, with the 2025 COLA set to rise 2.5%.
By Sandra Block Published